Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG. Therapeutic targeting of trained immunity. Nat Rev Drug Discov. 2019;18(7):553–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamrani A, Nasiri H, Hassanzadeh A, Ahmadian Heris J, Mohammadinasab R, Sadeghvand S, Sadeghi M, Valedkarimi Z, Hosseinzadeh R, Shomali N, et al. New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses. Cell Commun Signal. 2024;22(1):56.

Article  PubMed  PubMed Central  Google Scholar 

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104.

Article  PubMed  Google Scholar 

Herberman RB, Holden HT, Ting CC, Lavrin DL, Kirchner H. Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice. Cancer Res. 1976;36(2 pt 2):615–21.

CAS  PubMed  Google Scholar 

Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626(8000):727–36.

Article  CAS  PubMed  Google Scholar 

Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85–100.

Article  PubMed  Google Scholar 

Page A, Chuvin N, Valladeau-Guilemond J, Depil S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024;21(4):315–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenberg SA. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod. 1984;3(5):501–11.

CAS  PubMed  Google Scholar 

Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno M, Sakai F, Kato A, Tanabe M, Enoki T, et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. 2015;13:277.

Article  PubMed  PubMed Central  Google Scholar 

Ciurea SO, Kongtim P, Srour S, Chen J, Soebbing D, Shpall E, Rezvani K, Nakkula R, Thakkar A, Troy EC, et al. Results of a phase I trial with haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol. 2024;99(5):890–9.

Article  CAS  PubMed  Google Scholar 

Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671–88.

Article  CAS  PubMed  Google Scholar 

Stokic-Trtica V, Diefenbach A, Klose CSN. NK cell development in times of innate lymphoid cell diversity. Front Immunol. 2020;11:813.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends Immunol. 2013;34(12):573–82.

Article  CAS  PubMed  Google Scholar 

Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–18.

Article  CAS  PubMed  Google Scholar 

Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol. 2017;31:37–54.

Article  CAS  PubMed  Google Scholar 

Spits H, Bernink JH, Lanier L. NK cells and type 1 innate lymphoid cells: partners in host defense. Nat Immunol. 2016;17(7):758–64.

Article  CAS  PubMed  Google Scholar 

Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47(5):820–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruno A, Ferlazzo G, Albini A, Noonan DM. A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst. 2014;106(8):dju200.

Article  PubMed  PubMed Central  Google Scholar 

Collins PL, Cella M, Porter SI, Li S, Gurewitz GL, Hong HS, Johnson RP, Oltz EM, Colonna M. Gene Regulatory Programs Conferring Phenotypic Identities to Human NK Cells. Cell. 2019;176(1–2):348-360 e312.

Article  CAS  PubMed  Google Scholar 

Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.

Article  CAS  PubMed  Google Scholar 

Kirchhammer N, Trefny MP, Natoli M, Brucher D, Smith SN, Werner F, Koch V, Schreiner D, Bartoszek E, Buchi M, et al. NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity. Sci Transl Med. 2022;14(653):eabm9043.

Article  CAS  PubMed  Google Scholar 

Victorino F, Sojka DK, Brodsky KS, McNamee EN, Masterson JC, Homann D, Yokoyama WM, Eltzschig HK, Clambey ET. Tissue-resident NK cells mediate ischemic kidney injury and are not depleted by anti-asialo-GM1 antibody. J Immunol. 2015;195(10):4973–85.

Article  CAS  PubMed  Google Scholar 

Cortez VS, Cervantes-Barragan L, Robinette ML, Bando JK, Wang Y, Geiger TL, Gilfillan S, Fuchs A, Vivier E, Sun JC, et al. Transforming growth factor-beta signaling guides the differentiation of innate lymphoid cells in salivary glands. Immunity. 2016;44(5):1127–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, Kubota M, Matsumoto R, Thapa P, Szabo PA, et al. Tissue determinants of human NK cell development, function, and residence. Cell. 2020;180(4):749-763 e713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Tian Z, Peng H. Tissue-resident NK cells and other innate lymphoid cells. Adv Immunol. 2020;145:37–53.

Article  CAS  PubMed  Google Scholar 

Becker-Hapak MK, Shrestha N, McClain E, Dee MJ, Chaturvedi P, Leclerc GM, Marsala LI, Foster M, Schappe T, Tran J, et al. A fusion protein complex that combines IL-12, IL-15, and IL-18 signaling to induce memory-like NK cells for cancer immunotherapy. Cancer Immunol Res. 2021;9(9):1071–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jost S, Lucar O, Lee E, Yoder T, Kroll K, Sugawara S, Smith S, Jones R, Tweet G, Werner A, et al. Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis. Sci Immunol. 2023;8(90):eadi3974.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123.

Article  PubMed  PubMed Central  Google Scholar 

Erokhina SA, Streltsova MA, Kanevskiy LM, Grechikhina MV, Sapozhnikov AM, Kovalenko EI. HLA-DR-expressing NK cells: effective killers suspected for antigen presentation. J Leukoc Biol. 2021;109(2):327–37.

Article